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Background: The availability of several definitions of the metabolic syndrome has created 
potential confusion concerning its prognostic utility. At present, little data exist about the risk 
factors associated with metabolic syndrome in diabetic patients.
Aim: To identify risk factors associated with metabolic syndrome in patients with type 2 diabetes 
mellitus according to three diagnostic criteria: World Health Organization (WHO), Third Report 
of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults – Adult Treatment Panel III (NCEP-ATP III), 
and International Diabetes Federation (IDF).
Subjects and methods: A logistic regression model was used to identify demographic, 
clinical, and lifestyle variables related with metabolic syndrome (N = 1259).
Results: Hypertension, dyslipidemia, and glycosylated hemoglobin (HbA1c) $7% were 
associated with increased risk of WHO-defined metabolic syndrome (odds ratio [OR], 2.33; 
95% confidence interval [CI]: 1.60–3.40; OR, 1.79 95% CI: 1.25–2.55; and OR, 1.58; 95% 
CI: 1.12–2.22, respectively). The risk of presenting metabolic syndrome according to NCEP-
ATP III criteria was increased in female patients (OR, 2.02; 95% CI: 1.37–2.97), elevated fasting 
glucose levels (OR, 5.99; 95% CI: 3.56–10.07), dyslipidemia (OR, 2.28; 95% CI: 1.57–3.32), 
hypertension (OR, 2.36; 95% CI: 1.59–3.53), and endocrine disorders (OR, 1.64; 95% CI: 
1.06–2.57). For the IDF criteria, female patients and patients with left ventricular hypertrophy 
or insulin treatment were at higher risk of metabolic syndrome (OR, 4.00; 95% CI: 2.35–6.80; 
OR, 2.72 95% CI: 1.22–6.04; and OR, 1.96 95% CI: 1.24–3.11, respectively).
Conclusions: The risk factors for metabolic syndrome in type 2 diabetes mellitus patients are 
highly dependent on the criteria used to define the syndrome, supporting the need for a single 
clinically useful and epidemiologically useful definition.
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Introduction
Patients with metabolic syndrome, also known as cardiometabolic syndrome or insulin 
resistance syndrome, are at greater risk of cardiovascular disease regardless of a previous 
history of cardiovascular events.1,2 This is particularly relevant in patients with type 2 
diabetes mellitus, who are at even greater cardiovascular risk.3 In fact, cardiovascular com-
plications are the most common cause of morbidity and mortality in this population.4Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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The availability of several definitions of metabolic 
syndrome has created potential confusion concerning its prog-
nostic utility. At present, little data exist about the risk factors 
associated with metabolic syndrome in diabetic patients.5,6 The 
aim of this analysis was to identify the risk factors associated 
with metabolic syndrome in a large sample of patients with 
type 2 diabetes mellitus in Spain according to three diagnostic 
criteria: World Health Organization (WHO), the Third Report 
of the National Cholesterol Education   Program Expert Panel 
on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults – Adult Treatment Panel III (NCEP-
ATP III), and the International Diabetes Federation (IDF). 
The main difference between these diagnostic criteria lies in 
the way in which the various components for the diagnosis 
are grouped and combined. The WHO criteria focus on the 
presence of diabetes, glucose intolerance or insulin resistance 
together with the presence of at least two other components 
from a list of five components. On the other hand, the NCEP-
ATP III criteria give the same weight to abdominal obesity, 
hypertension, hyperglycemia, hypertriglyceridemia and low 
HDL-cholesterol (three or more of these components must 
be present for a diagnosis). Finally, the IDF criteria are 
similar to NCEP-ATP III although emphasizing the presence 
of abdominal obesity – with cutoff points tailored to ethnic 
origin – compared with other four components of which at 
least two or more must be present.7
Subjects and methods
Study design, subjects, and methods have been described 
previously.7 This is a secondary analysis of the data from a 
nationwide, cross-sectional, naturalistic, multicenter study 
carried out in outpatient clinics in Spain. The study was 
performed between November 2004 and July 2005. Included 
patients had type 2 diabetes mellitus diagnosed accord-
ing to the American Diabetes Association (ADA) criteria   
and were aged 18 years or older. The local ethical review 
board of the Hospital Clínico San Carlos (Madrid, Spain) 
provided approval of the study protocol and the study was 
conduc  ted in accordance with the principles of the Declara-
tion of Helsinki.
We explored the associations between significant demo-
graphic, clinical, and lifestyle variables and the prevalence 
of metabolic syndrome (diagnosed according to WHO, 
NCEP-ATPIII, and IDF criteria) by means of a chi-square 
test for categorical variables and a Student’s t-test for 
continuous variables. The sociodemographic and lifestyle 
variables included in the analysis were age, geographical 
region, education, smoking status, and physical activity; the 
clinical variables were body mass index (BMI), glycosylated 
hemoglobin (HbA1c) and fasting plasma glucose (FPG) values, 
diagnosis of dyslipidemia, hypertension, cardiovascular dis-
ease, heart failure, left ventricular hypertrophy, or existing 
comorbidities. All the variables with a P value , 0.1 in the 
bivariate analysis were included as independent variables in 
a multivariate logistic regression model. This cut-off point 
was chosen to ensure that all possibly related variables were 
included in the logistic regression model.
Results
Out of the 1345 patients selected, 1259 met the inclusion 
criteria and participated in the study (622 from primary care 
and 637 from internal medicine settings). Patients’ mean age 
(standard deviation [SD]) was 64.7 (10.7) years, and 57.1% 
of patients were male. Physical activity was low in 61.9% 
of patients, of whom 31.4% had a sedentary lifestyle. Mean 
time (SD) from type 2 diabetes mellitus diagnosis was 7 
years (7.3). The majority of patients were on diet and exer-
cise (88.2%), and 75.9% of the sample was receiving oral 
antihyperglycemic medications (OAM). Twenty percent were 
on insulin treatment. In addition, a total of 70.8% of patients 
had been diagnosed with hypertension, dyslipidemia (67.1%), 
or left ventricular hypertrophy (12.3%).
Results from the logistic regression analyses are shown in 
Table 1. The presence of metabolic syndrome according to the 
WHO definition was significantly associated with age, intense 
and moderate physical activity, dyslipidemia, hypertension, 
treatment with OAM, and HbA1c levels $7%. The existence 
of dyslipidemia, hypertension, and HbA1c $7% in patients 
was related to higher odds ratios for metabolic syndrome. 
In contrast, older age ($65 years) and intense and moderate 
physical activity attenuated the risk of metabolic syndrome. 
For NCEP-ATP III definition, age, gender, moderate and 
intense physical activity, elevated FPG levels, dyslipidemia, 
hypertension, treatment with OAM, and the presence of 
endocrine disorders were independently associated with 
metabolic syndrome. The risk of metabolic syndrome was 
elevated in females (twofold), patients with elevated fasting 
plasma glucose levels (sixfold), dyslipidemia, hypertension, 
and endocrine disorders. Finally, the prevalence of metabolic 
syndrome as per IDF definition was associated with gender, 
moderate physical activity, insulin treatment, and left ven-
tricular hypertrophy. Women (fourfold), patients not treated 
with insulin, and patients with left ventricular hypertrophy 
were at higher risk of IDF-defined metabolic syndrome than 
men, patients treated with insulin, and patients without left 
ventricular hypertrophy, respectively.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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The risk of having metabolic syndrome for women with 
type 2 diabetes mellitus was higher by the IDF criteria than the 
NCEP-ATP III criteria. An older age ($65 years) and intense 
physical activity appeared to be protective factors against 
metabolic syndrome according to both WHO and NCEP-ATP 
III, whereas the presence of dyslipidemia, hypertension, and 
treatment with OAM showed similar increased risk by both 
diagnostic definitions. Finally, moderate physical activity 
seemed to be associated with reduced risk by NCEP-ATP III, 
IDF, and WHO definitions of metabolic syndrome.
Discussion
Previously published data from this study showed that in 
this population, the prevalence rates of metabolic syndrome 
according to WHO, NCEP-ATP III, and IDF were different 
(71.5%, 78.2%, and 89.5%, respectively).7 Further, the data 
presented here provide evidence that in subjects with type 2 
diabetes mellitus, the existence of dyslipidemia, hypertension, 
and HbA1c levels of $7% increases the risk of presenting 
metabolic syndrome, according to WHO-defined criteria. 
For the NCEP-ATP III-defined metabolic syndrome, the risk 
is increased in women, subjects with elevated FPG levels, 
dyslipidemia, hypertension, and endocrine disorders. For the 
IDF criteria, women, patients treated with insulin, and patients 
with left ventricular hypertrophy (may be related to hyperten-
sion) are at higher risk of metabolic syndrome. Although there 
is some disparity in the degree of physical activity related to 
the NCEP-ATP III, IDF, and WHO definitions, it seems that 
exercise training would be associated in this study with a 
decreased risk of metabolic syndrome. This is the first study 
to show that metabolic syndrome, according to all three defini-
tions (WHO, NCEP-ATP III, and IDF), in a large sample of 
Spanish patients with type 2 diabetes, is independently associ-
ated with different risk factors (metabolic and non-metabolic) 
depending on the diagnostic criteria used, likely due in part 
to the differences in the cut-off points. Nevertheless, all three 
criteria provided greater odds ratios for the cardiovascular 
risk factors studied. In fact, previous studies have reported an 
increased cardiovascular risk associated with the presence of 
metabolic syndrome.8,9 This is not surprising since metabolic 
syndrome contains well-established cardiovascular risk factors 
such as hypertension and dyslipidemia.
In summary, the risk factors associated with the pres-
ence of metabolic syndrome in a population with type 2 
diabetes mellitus are highly dependent on the criteria used to 
define metabolic syndrome, supporting the need for a single 
common clinically and epidemiologically useful definition 
of metabolic syndrome. The identification and clinical man-
agement of the high-risk groups will contribute significantly 
to metabolic syndrome prevention in patients with type 2 
diabetes mellitus. 
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Table 1 Odds ratios for having metabolic syndrome according to WHO, NCEP-ATPIII, and IDF definitions
WHO 
OR [95% CI]
NCEP-ATPIII 
OR [95% CI]
IDF 
OR [95% CI]
Age ($65 years vs ,65 years) 0.48 [0.34–0.69] 0.59 [0.41–0.87] –
gender (female vs male) – 2.02 [1.37–2.97] 4.00 [2.35–6.80]
Physical activity
  Low (,2 h/week vs sedentarism) 0.82 [0.52–1.27] 0.66 [0.40–1.09] 0.62 [0.35–1.09]
  Moderate (2–4 h/week vs sedentarism) 0.43 [0.27–0.67] 0.43 [0.26–0.72] 0.42 [0.24–0.74]
  intense (.6 h/week vs sedentarism) 0.44 [0.26–0.76] 0.30 [0.17–0.53] 0.53 [0.27–1.04]
hbA1c (.7% vs #7%) 1.58 [1.12–2.22] 1.08 [0.74–1.56] –
Fasting glucose (elevated vs normal) 1.36 [0.78–2.35] 5.99 [3.56–10.07] –
Dyslipidemia (yes vs no) 1.79 [1.25–2.55] 2.28 [1.57–3.32] –
hypertension (yes vs no) 2.33 [1.60–3.40] 2.36 [1.59–3.53] –
Treatment with OAM (yes vs no) 1.54 [1.04–2.29] 1.63 [1.07–2.48] –
Treatment with insulin (yes vs no) – – 1.96 [1.24–3.11]
endocrine disorders (yes vs no) 1.44 [0.97–2.12] 1.64 [1.06–2.57] –
Left ventricular hypertrophy (yes vs no) 1.68 [0.95–2.97] 1.32 [0.73–2.41] 2.72 [1.22–6.04]
Note: Variables not included in the model due to lack of statistical significance in the bivariate analysis.
Abbreviations: WhO, World health Organization; nceP-ATPiii, Third Report national cholesterol education Program; iDF, international Diabetes Federation; OR, odds 
ratio; OAM, oral antihyperglycemic medication; CI, confidence interval; HbA1c, hemoglobin A1c.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
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